Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations

详细信息	查看全文 | 推荐本文 |

• 作者：Ameneh Khatami^a ; ^{ameneh.khatami@paediatrics.ox.ac.uk} ; Matthew D. Snape^a ; Elizabeth Davis^a ; Helen Layton^a ; Tessa John^a ; Ly-Mee Yu^b ; Peter M. Dull^c ; Christopher J. Gill^c ; Tatjana Odrjlin^c ; Simon Dobson^d ; Scott A. Halperin^e ; Joanne M. Langley^e ; Shelly A. McNeil^e ; Andrew J. Pollard^a
• 关键词：Meningococcal ; Quadrivalent conjugate vaccine ; Immune response ; Persistence ; Childhood
• 刊名：Vaccine
• 出版年：2012
• 期刊代码：89_0264410x
• 类别：imm
• 出版时间：16 April, 2012
• 卷：30
• 期：18
• 页码：2831-2838
• 文件大小：619 K

摘要

Background and aims

Serogroup A, C, W-135 and Y meningococcal (MenACWY) conjugate vaccines are recommended for routine adolescent immunisation in the United States and Canada. We evaluated the persistence of bactericidal antibodies through early childhood, following infant immunisation with varying schedules of MenACWY-CRM₁₉₇ vaccine.

Methods

UK and Canadian infants were immunised with 2-3 doses of MenACWY-CRM₁₉₇ or 2 doses of serogroup C meningococcal (MenC) conjugate vaccine, and either MenACWY-CRM₁₉₇, 1/5 dose of MenACWY polysaccharide vaccine or no booster at 12 months. Control groups recruited at 60 months had received country-specific infant doses of MenC conjugate vaccine. hSBA titres were measured in participants at 40 and 60 months of age.

Results

382 children were enrolled in 12 groups (22-40 per group). By age 60 months, 3-11%of children primed and boosted with MenACWY-CRM₁₉₇ had hSBA titres 鈮?#xA0;1:8 against serogroup A, 14-45%against serogroup C, 57-85%against serogroup W-135 and 42-71%against serogroup Y. Children primed with MenC and boosted with MenACWY-CRM₁₉₇ had similar results, except for serogroup C (59%). In age-matched controls administered MenC vaccine at 2, 3, and 4 months (UK), 2 and 12 months or 12 months only (Canada), percentages with hSBA titres 鈮?#xA0;1:8 were 0-3%, 29-53%, 34-36%and 10-29%against serogroups A, C, W-135 and Y respectively.

Conclusions

Serogroup-specific bactericidal antibody wane following infant immunisation with MenACWY-CRM₁₉₇, most markedly against serogroup A. Best persistence against serogroup C is observed with MenC conjugate vaccine priming and MenACWY-CRM₁₉₇ at 12 months, compared to schedules using only MenACWY-CRM₁₉₇, with the potential for providing broader protection compared to monovalent MenC vaccines alone.